Q’Apel Medical Announces CE Mark Approval for Armadillo SelectFlex™ Neurovascular Access System

FREMONT, Calif., Jan. 13, 2025 /PRNewswire/ -- Q'Apel Medical (Q'Apel), a privately held medical device company focused on revolutionizing neurovascular interventions, today announced it has received CE mark certification for its Armadillo SelectFlex™ Neurovascular Access System. The first-of-its-kind 7F system features the patented SelectFlex™ Technology and is indicated for the introduction of interventional devices into the neurovasculature.

“Neurovascular access can be extremely challenging. The tortuous anatomy requires flexibility to navigate the tight twists and turns, however, flexible access catheters tend to lack the support and stability required for device delivery once positioned,” commented Pascal Jabbour, MD, FAANS, FACS, FAHA, The Angela and Richard T. Clark Distinguished Professor of Neurological Surgery and Radiology, Division Chief of Neurovascular Surgery & Endovascular Neurosurgery at Thomas Jefferson University Hospital in Philadelphia, PA. “Armadillo provides a one-and-done solution that simplifies access procedures. It is designed to place full control in the hands of the operator as it allows users to transform the catheter from highly trackable to highly supportive as needed throughout the procedure with the simple injection or withdrawal of just 0.2cc of saline.”

Sign up for Blog Updates